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Abstract
Background: Non-invasive prenatal testing (NIPT) for Down’s syndrome (DS) using cell free fetal DNA in maternal blood has
the potential to dramatically alter the way prenatal screening and diagnosis is delivered. Before NIPT can be implemented
into routine practice, information is required on its costs and benefits. We investigated the costs and outcomes of NIPT for
DS as contingent testing and as first-line testing compared with the current DS screening programme in the UK National
Health Service.
Methods: We used a pre-existing model to evaluate the costs and outcomes associated with NIPT compared with the
current DS screening programme. The analysis was based on a hypothetical screening population of 10,000 pregnant
women. Model inputs were taken from published sources. The main outcome measures were number of DS cases detected,
number of procedure-related miscarriages and total cost.
Results: At a screening risk cut-off of 1:150 NIPT as contingent testing detects slightly fewer DS cases, has fewer procedure-
related miscarriages, and costs the same as current DS screening (around UK£280,000) at a cost of £500 per NIPT. As first-line
testing NIPT detects more DS cases, has fewer procedure-related miscarriages, and is more expensive than current screening
at a cost of £50 per NIPT. When NIPT uptake increases, NIPT detects more DS cases with a small increase in procedure-
related miscarriages and costs.
Conclusions: NIPT is currently available in the private sector in the UK at a price of £400-£900. If the NHS cost was at the
lower end of this range then at a screening risk cut-off of 1:150 NIPT as contingent testing would be cost neutral or cost
saving compared with current DS screening. As first-line testing NIPT is likely to produce more favourable outcomes but at
greater cost. Further research is needed to evaluate NIPT under real world conditions.
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Introduction
In the UK the National Screening Committee (NSC) sets the
standards for antenatal screening and recommends that all
pregnant women are offered Down’s syndrome (DS) screening.
Ideally this is the combined screening test performed between 11
and 14 weeks gestation. In current National Health Service (NHS)
practice this has a detection rate of around 85% and a screen
postive rate around 2.5% [1]. Women with a risk of 1:150 or
greater of the baby having DS are offered an invasive diagnostic
test (chorionic villus sampling (CVS) or amniocentesis), providing
definitive diagnosis as to whether or not the baby has DS. If full
karyotyping or microarray analysis is performed other chromo-
somal abnormalities may be detected.
Current invasive diagnostic tests have a risk of miscarriage of
0.5–1% [2]. The discovery of cell free fetal DNA (cffDNA) in
maternal blood [3] has led to safer non-invasive approaches to
prenatal testing where aneuploidies are detected via a maternal
blood test from 10 weeks gestation [4]. Several large-scale validity
studies have been conducted to evaluate non-invasive prenatal
testing (NIPT) for DS based on next generation sequencing [5–
12]. Detection rates for DS are typically greater than 99% with a
false positive rate of 0.1–1%. NIPT can also detect other
aneuploidies including trisomy 18 (99% accurate) and trisomy
13 (up to 90% accurate) [9–12]. The small false positive rate for
DS means NIPT should be confirmed by invasive testing [13–15].
NIPT for DS as well as trisomy 18 and 13 is now offered through
commercial providers in several countries including the USA,
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Germany, Hong Kong and China. It is also available in the private
sector in the UK, with prices varying from £400–£900 [16] and
samples being sent for testing overseas.
In publicly funded health care systems like the UK NHS, NIPT
for DS has the potential to dramatically alter the way prenatal
screening and diagnosis is delivered. Before NIPT can be
implemented into routine practice, further information is required
to identify where it fits in the screening pathway, based on the
likely costs and benefits. Several studies have investigated costs and
benefits of NIPT for DS using cell free fetal DNA in maternal
blood [6,17–21] but there is no evidence that is directly relevant to
the UK NHS. Palomaki et al [6] calculated the costs and outcomes
of NIPT as contingent testing for DS in the USA. In 100,000
women at high risk for DS, they calculated that invasive testing
alone would detect 3,000 DS cases and cost US$100 million with
500 procedure-related losses. NIPT followed by invasive testing in
those with positive results would detect 2,958 DS cases at cost of
US$3.9 million and 20 procedure-related losses. The authors
assumed 100% uptake of NIPT and invasive testing and did not
include the cost of NIPT.
Wald and Bestwick [17] investigated the costs and outcomes of a
protocol combining DS screening and NIPT, where women at
highest risk for DS following screening receive NIPT. Results are
presented for different assumptions about the cost of NIPT and the
proportion of women eligible for NIPT. The analysis did not
include costs and outcomes associated with invasive diagnostic
testing.
Garfield and Armstrong [18] assessed the costs and outcomes of
NIPT as contingent testing for trisomies 13, 18 and 21 in the USA.
In a hypothetical cohort of 100,000 pregnancies they calculated
that NIPT as contingent testing reduces the number of procedure-
related fetal losses from 60 to 20, increases the number of DS cases
detected from 148 to 170, and reduces prenatal testing costs by
1%. They calculated that NIPT as contingent testing is likely to be
cost saving at a price of up to US$1,200 per test.
Song et al [19] assessed the cost-effectiveness of NIPT for DS in
the USA, comparing first trimester combined screening, integrated
screening and NIPT (without conventional screening in women
aged 35 years or more, and following a positive screening result in
women younger than 35 years). At a cost of US$795, NIPT
dominated the other strategies, detecting more DS cases, with
fewer procedure-related miscarriages and lower costs. The cost
savings were mainly due to reductions in the costs of managing DS
during the first five years of life. The authors did not include the
medical costs associated with unaffected children during their first
five years of life.
Ohno and Caughey [20] analysed the cost-effectiveness of
NIPT as contingent testing versus NIPT as a diagnostic test that
did not require confirmatory invasive diagnostic testing in the
USA. Making assumptions about the quality adjusted life
expectancy beyond pregnancy from testing, they concluded that
NIPT as contingent testing was cost-effective. The analysis did not
compare NIPT versus current practice, so it was not possible to
determine if NIPT ought to be adopted.
Cuckle et al [21] investigated factors affecting the cost of
avoiding a DS birth using either universal NIPT or NIPT as
contingent testing versus conventional screening in the USA. They
found that unit costs of NIPT and uptake of NIPT were important
factors affecting cost-effectiveness. The high cost of NIPT
(US$500-2000 compared with US$150 for the Combined test)
meant that universal NIPT was unlikely to be cost-effective.
Our aim was to assess the costs and outcomes of NIPT for DS as
contingent testing and as first-line testing compared with the
current DS screening programme in the UK NHS. We find that
NIPT as contingent testing can produce favourable outcomes at
the same cost compared with current DS screening. As first-line
testing NIPT is likely to produce more favourable outcomes but at
greater cost.
Materials and Methods
Ethics Statement
Data used to populate the model were obtained from publicly
available sources listed in Table 1. All the data were group
averages taken from multiple previously published sources, based
on patient data that were de-identified prior to being used in our
study. Hence, ethical approval was not required.
Including NIPT in the DS Screening Pathway
We evaluate two approaches to introducing NIPT into the
current DS screening pathway. For current DS screening in the
UK, the components most relevant for this study are that all
pregnant women are offered DS screening and those who are high
risk are offered an invasive test (Figure 1, Figure S1 in Supporting
Information). The first alternative we consider is with NIPT as
contingent testing. In this case, all pregnant women are offered DS
screening as before and those with a risk from DS screening above
a pre-specified level are offered NIPT rather than an invasive test
(Figure 2, Figure S2 in Supporting Information). Invasive testing is
then offered to those with abnormal NIPT results. The second
alternative is with NIPT as first-line testing, replacing the current
DS screening programme (Figure 3). In this case women are not
offered DS screening, but are offered NIPT instead and invasive
testing is offered to those with abnormal NIPT results. We focused
on DS, and did not consider NIPT for trisomies 18 and 13 as DS is
the focus of the National Screening Programme.
Overview of Modelling Approach
The Decision Planning Tool (DPT) is a complex publicly
available decision analytic model developed, using Microsoft Excel
1997–2003, by the Peninsula Technology Assessment Group
(PenTAG) [22]. It was commissioned by the NHS Fetal Anomaly
Screening Programme (FASP), with partial funding from the
Knowledge Transfer Partnership (KTP), as a health economic
model to support decision-makers and commissioners when
assessing the costs and effects of DS screening. The model was
developed to include a decision tree structure for six DS screening
strategies used within the NHS (double, triple, quadruple,
combined, serum integrated and integrated tests) following
nationally agreed standards and pathways provided by the NHS
FASP. With permission, we amended the DPT to include NIPT as
contingent testing and first-line testing. The DPT uses a range of
published and publically available national data on the UK costs
and estimated prevalence of DS in the UK population as well as
the costs of different aspects of DS screening and diagnostic
provision. It was specifically designed to assess the costs and
benefits of different DS screening tests. For this study, we assumed
that all women screened during the first trimester receive the
combined test (comprising nuchal translucent measurement
combined with analysis of Pregnancy-associated plasma protein-
A (PAPP-A) and Free beta-human chorionic gonadotrophin (b-
hCG)), and all screened during the second trimester received the
quadruple test (Alphafetoprotein (AFP), Free b-hCG or Total
hCG, unconjugated oestrial (uE3), and Inhibin-A), since these are
recommended tests in the UK [23]. The conclusions do not
change when other screening tests are used instead. All stages of
the DS screening pathways described in the Figures are accounted
for in the adapted DPT model. The perspective was the National
Cost of NIPT for DS
PLOS ONE | www.plosone.org 2 April 2014 | Volume 9 | Issue 4 | e93559
Table 1. Key model inputs.
Parameter Value Source/reference
Outcomes
Maternal age (%) 0.0024–0.0165 by year of maternal
age from #13 years to $50 years
[24]
Prevalence of Down’s syndrome (%) 0.1–2.6 by gestational week and maternal age [25]
Screening late arrivals (%) 15 [1]
Screening uptake (%) 69 [26]
Screening test performance (DR [%]; FPR [%])
Combined test with screening risk
cut-off of 1 in
150 85.0; 2.5 [27]
500 94.0; 7.0
1000 96.0; 12.0
2000 98.0; 19.0
Quadruple free b-hCG test 80.5; 4.0 [28]
Weekly spontaneous fetal loss (%)
DS affected pregnancies 0.5–7.1 by gestational week [29]
Unaffected pregnancies 0.04–0.07 by maternal age [30]
NT measurement failures (%) 14–19 by gestational week [31]
Invasive diagnostic test uptake (%)
Unaffected pregnancies 80 [32]
DS pregnancies 90 [32]
Invasive diagnostic test performance (DR [%];
sample failure rate [%]; procedural miscarriage rate [%])
CVS/QF-PCR 100; 1.3; 0.5 [33], [30], [33]
Amniocentesis/full karyotyping 100; 0.8; 0.5 [33], [30], [33]
TOP uptake (%) 92.1 [34]
Live birth outcomes (%)
Vaginal live birth 75.2 [35]
Caesarean live birth 24.8 [35]
Costs
Costs of screening
Combined test 27 [22]
Quadruple free b-hCG test 35 [22]
Cost invasive diagnostic test (£)
CVS/QF-PCR 479 [36]
Amniocentesis/full karyotyping 479 [36]
Cost fetal loss (£)
Spontaneous 511 [36]
Due to CVS or amniocentesis 511 [36]
Cost TOP (£)
First trimester 697 [36]
Second trimester 882 [36]
Cost live birth outcomes (£)
Vaginal live birth 1,341 [36]
Caesarean live birth 2,436 [36]
NIPT
Uptake of NIPT (%)
As contingent testing
Base case
Unaffected pregnancies 80 Assumption**
DS pregnancies 90 Assumption**
Cost of NIPT for DS
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DS screening programme in the NHS in the UK. The time
horizon over which costs and outcomes are measured is the
duration of pregnancy; discounting is therefore unnecessary. As in
the DPT, costs are calculated in 2011/12 UK£, inflated from
reported values where appropriate.
Model Inputs
All model inputs, except those for NIPT, for DS screening test
performance at different risk cut-offs, and procedural miscarriage
rates for invasive diagnostic tests, are as used in the original DPT
model and taken from published sources [1], [22], [24–36]
(Table 1). The screening population is representative of the
screening population of England. Maternal age distributions are
from the Office for National Statistics’ annual maternity statistics
[24]. The underlying prevalence of DS varied by maternal age and
gestational ages [25].
Eighty-five per cent of women were offered DS screening during
the first trimester using the combined test; 15% were booked after
14 weeks’ gestation and were offered screening in the second
trimester with the quadruple test [1]. The uptake rate for both tests
was 69% [26].
The detection rate (DR) and false positive rate (FPR) for the
combined test were based on different screening risk cut-offs from
1:150 to 1:2000 [27]. We used the 1:150 risk cut-off to evaluate the
Table 1. Cont.
Parameter Value Source/reference
Alternative scenario 100* Assumption
Alternative scenario 100*, uptake of screening increase from 69% to 79% Assumption
As first-line screening
Base case 69 Assumption***
Alternative scenario 79 Assumption
NIPT performance (DR [%]; FPR [%]; sample failure rate [%];
procedural miscarriage rate [%])
99; 1; 5; 0 Assumption based on Table 2
Cost of NIPT 50, 250, 500, 750 Assumption
Cost of taking blood sample 3 [36]
*For both unaffected and DS affected pregnancies.
**As for invasive diagnostic tests.
***As for DS screening. DS = Down’s syndrome; NT = nuchal translucency; CVS = chorionic villus sampling; QF-PCR = Quantitative Fluorescence Polymerase Chain
Reaction; TOP = termination of pregnancy; DR = detection rate; FPR = false positive rate
doi:10.1371/journal.pone.0093559.t001
Figure 1 First trimester screening pathway: current DS screening. DS = Down’s syndrome; NT = nuchal translucency; CVS = chorionic villus
sampling; QF-PCR = Quantitative Fluorescence Polymerase Chain Reaction; TOP = termination of pregnancy. See Figure S1 in Supporting
Information for the second trimester screening pathway.
doi:10.1371/journal.pone.0093559.g001
Cost of NIPT for DS
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costs and outcomes associated with current DS screening, and we
evaluated NIPT as contingent testing using different screening risk
cut-offs from 1:150 to 1:2000. The DR and FPR for the quadruple
test were 80.5% and 4%, respectively [28].
CVS (amniocentesis) uptake is the proportion of women who
accept a first trimester (second trimester) invasive prenatal
diagnostic investigation after receiving a high risk screening result.
Evidence suggests that for both tests the uptake is 80% for
Figure 2 First trimester screening pathway: NIPT as contingent testing. DS = Down’s syndrome; NT = nuchal translucency; NIPT = non-
invasive prenatal testing; CVS = chorionic villus sampling; QF-PCR = Quantitative Fluorescence Polymerase Chain Reaction; TOP = termination of
pregnancy. See Figure S2 in Supporting Information for the second trimester screening pathway.
doi:10.1371/journal.pone.0093559.g002
Figure 3 NIPT as first-line testing. DS = Down’s syndrome; NT = nuchal translucency; NIPT = non-invasive prenatal testing; CVS = chorionic
villus sampling; QF-PCR = Quantitative Fluorescence Polymerase Chain Reaction; TOP = termination of pregnancy.
doi:10.1371/journal.pone.0093559.g003
Cost of NIPT for DS
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unaffected pregnancies and 90% for DS affected pregnancies [32].
We use these values in the model of current screening and also, in
the absence of data, for uptake of invasive diagnostic testing after
NIPT. Values for invasive test detection rates and sample failure
rates were taken from published figures [30,33]. The original DPT
assumes procedural miscarriage rates of 1% for amniocentesis and
2% for CVS. Based on a recent review [2], which found rates of
0.5–1% for both types of test, we assumed a procedural
miscarriage rate for CVS and amniocentesis of 0.5%.
The probability of weekly spontaneous fetal loss for unaffected
pregnancies was assumed to be 0.0012 during gestational weeks 10
to 25 and 0.00034 during weeks 26 to 40 [30]. For DS affected
pregnancies, it was 0.07067 in weeks 10 to 15 and 0.0051 in weeks
16 to 40 [29]. Termination of pregnancy (TOP) uptake is the
proportion of women who accept to terminate their pregnancy
after receiving a positive diagnosis for DS and is estimated to be
92.1% [34]. Information on the proportion of women who have a
vaginal or caesarean delivery is derived from annual maternity
services data [35].
The unit costs of the combined test and the quadruple test were
£27 and £35, respectively, including staffing, administration,
equipment, overheads, delivery of low risk results via 2nd class mail
and high risk results via telephone. The weighted unit cost per
CVS/QF-PCR and amniocentesis/full karyotype is estimated to
be £479 for each test [36]. The unit cost for spontaneous fetal loss
and fetal loss due to an invasive diagnostic procedure are both
estimated as £511. The unit cost of TOP was assumed to be £697
in the first trimester and £882 in the second trimester. Unit costs
for live birth outcomes were £1,341 for vaginal live birth and
£2,436 for caesarean live birth.
A number of studies have reported values for the sensitivity and
specificity of NIPT [5–12], with values ranging from 98.6%–100%
and 99.7–100%, respectively, and combined values of 99.33% and
99.94%, respectively (Table 2). There were few false negatives,
and these occurred in the larger whole genome sequencing studies.
We assumed a DR and FPR for NIPT of 99% and 1%,
respectively. The sample failure rate for the NIPT was assumed to
be 5%. We assumed that when sample failure occurred the cost of
another NIPT was incurred; sample failure with NIPT was
assumed not to occur more than once in each pregnancy. The
procedural fetal loss rate associated with NIPT was 0%. There is
limited evidence from the UK to suggest that uptake rate of NIPT
in a general DS screening population is higher than current testing
[37], a view supported by some small studies of women
undergoing NIPT for aneuploidy in the USA [38], but this is
currently unproven under real world conditions. For NIPT as
contingent screening, we therefore assumed in the base case that
uptake of NIPT would be the same as for invasive testing in the
current DS screening programme (80% for unaffected pregnancies
and 90% for DS affected pregnancies). We also investigated what
happened when the NIPT uptake rate increased to 100% and
when it increased to 100% with a ten percentage point increase in
the uptake of DS screening (69% to 79%). For NIPT as firs- line
testing we assumed in the base case that uptake of NIPT would be
the same as for DS screening (69%). We also investigated what
happened when NIPT uptake increased to 79%. Since NIPT is
currently not available via the NHS the actual cost of NIPT is
unknown. We therefore used a range of values and present results
for costs of NIPT of £50, £250, £500 and £750 per test. In the
private sector in the UK, prices for NIPT vary from £400–£900.
Figures using a value of £500 are presented, since this represents a
threshold value in our results; we do not present results using cost
greater than £750 since NIPT is not cost effective above this level;
values of £50 and £250 are used to illustrate the cost implications
if NIPT costs were to fall substantially beyond current levels in the
private sector. We assumed that samples for NIPT were collected
at the same time that blood samples for DS screening were
collected, and therefore no additional sampling costs were
incurred. We also examined an alternative scenario in which
women at high risk following DS screening are asked for an
additional blood sample for NIPT.
Outcome Measures
Results are reported for a hypothetical screening population of
10,000 pregnant women who are representative of the screening
population of England. The main outcomes are the number of DS
cases detected, the number of procedure-related miscarriages and
the combined cost of screening, NIPT and invasive diagnostic
tests. The cost of screening includes the cost of the screening test
(combined test in the first trimester, quadruple test in the second
trimester), the cost of repeat nuchal translucency measurements
and the cost of delivering the screening test results. We also report
the number of women undergoing screening, the number
undergoing NIPT, the number with a positive NIPT result, the
number having an invasive diagnostic test, the cost of screening,
the cost of NIPT, and the cost of invasive diagnostic tests. We
report each measure by screening risk cut-off and cost per NIPT
test, and separately for different scenarios of NIPT uptake. We also
report the costs of each strategy including the costs of pregnancy
outcomes.
Results
In the current DS screening programme using a screening risk
cut-off of 1:150, 6,882 pregnant women would undergo DS
screening, 161 would have an invasive diagnostic test, there would
be around one procedure-related miscarriage and 13 DS cases
detected (Table 3). The total cost would be £279,000 (Table 4).
Under base case assumptions concerning NIPT uptake, with
NIPT as contingent testing and at a screening risk cut-off of 1:150,
6,882 women would undergo DS screening, 154 would undergo
NIPT, 13 would have a positive NIPT result, 11 would have a
diagnostic test, there would be fewer than one procedure-related
miscarriage and 11 DS cases would be detected. The total cost
would be £213,000-£322,000 depending on the cost of NIPT. At
a screening risk cut-off of 1:150 NIPT as contingent testing results
in fewer procedure-related miscarriages (due to fewer invasive
diagnostic tests), slightly fewer DS cases being detected (due to the
number of women who are high risk according to NIPT but
choose not to have an invasive diagnostic test); and, it costs around
the same as current DS screening if the cost per NIPT is £500.
If the screening risk cut-off for NIPT was lowered to 1:500,
1:1000 or 1:2000 there is an increase in the number undergoing
NIPT, the number with a positive NIPT result, the number having
a diagnostic test, the number of procedure-related miscarriages
and the number of DS cases detected. Costs increase such that
with a screening risk cut-off of 1:2000 contingent testing with
NIPT costs slightly less than current screening if the cost per NIPT
is only £50.
With NIPT as first-line screening, 6,882 would undergo NIPT,
28 would have a positive NIPT result, 22 would have an invasive
diagnostic test, there would be less than one procedure-related
miscarriage and 16 DS cases would be detected. The total cost
would be £449,000–£5,266,000 depending on the cost of NIPT.
Hence NIPT as first-line screening results in fewer procedure-
related miscarriages (due to the lower numbers of invasive
diagnostic tests), more DS cases being detected (due to the greater
accuracy of NIPT as compared with DS screening as first-line
Cost of NIPT for DS
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testing), and costs more even than current DS screening if the cost
per NIPT is only £50.
When the costs associated with pregnancy outcomes were
included to the base case, these were sufficiently large and similar
between the different strategies to mask differences in screening
and diagnosis costs between DS screening and NIPT as contingent
testing (Table S1 in Supporting Information).
Results are presented using the same methodology but with
different assumptions about uptake in Supporting Information. In
the case of NIPT as contingent testing, compared with the
assumptions made in the base analysis in Tables 3 and 4, when
NIPT uptake increases, NIPT detects more DS cases with slightly
more procedure-related miscarriages and with a small increase in
costs (Tables S2–S3 in Supporting Information). If NIPT uptake
increases and the provision of NIPT as contingent testing leads to
an increase in uptake of DS screening, NIPT produces fewer
invasive diagnostic tests, fewer procedure-related miscarriages, and
detects more DS cases compared with current DS screening, for
the same or a modest increase in costs depending on the screening
risk cut-off (Tables S4–S5 in Supporting Information).
The national average unit cost for a phlebotomist to take a
blood sample is £3 [34]. If samples for NIPT were collected for
high-risk women following DS screening in a separate visit then
the cost associated with NIPT increased by a negligible amount.
For example, for NIPT as contingent testing with a screening risk
cut-off of 1:150 154 women undergo NIPT and the cost of the
extra blood sample is less than £500, making no appreciable
difference to the costs in Table 4.
Discussion
Main Findings
We analysed the costs and outcomes of NIPT for DS as
contingent testing and first-line testing compared with the current
DS screening programme. We found that at a screening risk cut-
off of 1:150 NIPT as contingent testing detects slightly fewer DS
cases, has fewer procedure-related miscarriages, and costs the
same as current DS screening (around UK£280,000) at a cost of
£500 per NIPT. NIPT is currently available in the private sector
in the UK with prices varying from £400–£900 [16]. If the cost of
NIPT in the NHS was at the lower end of this range then at a
screening risk cut-off of 1:150 NIPT as contingent testing would be
cost neutral or cost saving compared with current DS screening.
When the screening risk cut-off is lowered the cost per NIPT
would need to fall considerably for NIPT to be cost neutral
compared with current DS screening. As first-line testing NIPT
detects more DS cases, has fewer procedure-related miscarriages,
and is more expensive than current screening at a cost of £50 per
NIPT. When NIPT uptake increases, NIPT detects more DS cases
with slightly more procedure-related miscarriages and with a
modest increase in costs.
Table 4. Costs of testing strategies in a screening population of 10,000 pregnant women.
Testing strategy
Screening risk
cut-off (1 in)
Cost per
NIPT test
(A) Cost of
screening
(£000s)
(B) Cost of
NIPT (£000s)
(C) Cost of invasive
diagnostic tests
(£000s)* (A)+ (B)+ (C) (£000s)
DS screening using the combined
test
150 200 0 79 279
NIPT as contingent testing 150 £50 200 8 6 213
150 £250 200 39 6 244
150 £500 200 78 6 283
150 £750 200 116 6 322
500 £50 200 18 6 225
500 £250 200 91 6 298
500 £500 200 183 6 389
500 £750 200 274 6 480
1,000 £50 200 30 6 237
1,000 £250 200 149 6 356
1,000 £500 200 298 6 505
1,000 £750 200 448 6 655
2,000 £50 200 46 7 253
2,000 £250 200 230 7 438
2,000 £500 200 461 7 668
2,000 £750 200 691 7 898
NIPT as first-line screening £50 0 438 11 449
£250 0 1,642 11 1,825
£500 0 3,535 11 3,546
£750 0 5,255 11 5,266
69% uptake of DS screening using the combined test. 80% uptake of NIPT as contingent screening for unaffected pregnancies and 90% for affected.
pregnancies. 69% uptake of NIPT as first-line screening.
*Including procedural miscarriages. DS = Down’s syndrome; NIPT = non-invasive prenatal testing
doi:10.1371/journal.pone.0093559.t004
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Strengths and Limitations
A strength of our study is that we utilised a pre-existing
validated cost model of DS screening in the NHS, developed to aid
Trusts, commissioners and health professionals plan, improve and
monitor DS screening.
A limitation is the lack of data about the cost and uptake of
NIPT under real world conditions. Our study is designed to
inform the implementation of NIPT and since it is not
implemented it is unclear what the cost and uptake of NIPT will
be. We present results for a range of values. The £400–£900 price
range in the private sector includes the cost of samples being sent
and tested overseas; costs are likely to fall if testing is undertaken in
the UK, and costs of sequencing are decreasing over time. Further
research could evaluate the costs and benefits of UK-based testing
and the implications of this for the cost-effectiveness of NIPT.
There is limited evidence to suggest that uptake of NIPT in the
general pregnant population may be higher than current DS
screening [37] but actual values are unknown. We present results
assuming NIPT uptake will be the same as for current DS
screening and that it will be 100%, and find that our conclusions
are not very sensitive to the uptake rates used. We also assumed
that uptake of invasive diagnostic testing after a positive NIPT
result is the same as after being found high risk from DS screening.
Uptake of invasive diagnostic testing after NIPT may actually be
higher because NIPT has a higher positive predictive value than
DS screening (Song et al [19] assumed that 99% of patients
undergo invasive testing after a positive NIPT). This would mean
that the difference in DS cases detected between current DS
screening and NIPT as contingent testing will fall.
Another limitation is that NIPT can be used to test for trisomy
18, trisomy 13 and some sex chromosome aneuploidies; we have
only looked at NIPT for DS. One shortcoming of NIPT is that it
does not detect other chromosomal rearrangements, though this is
possible with invasive methods. We have not accounted for this on
our model, which focuses on DS. Prenatal diagnosis programmes
may need to consider the use of invasive tests in pregnancies where
the NIPT test is normal, but increased nuchal translucency or
other structural abnormalities suggest other chromosomal rear-
rangements [39,40]. This requires further evaluation when NIPT
is used in clinical practice.
Conclusions
Our study has two main implications. First, at a screening risk
cut-off of 1:150 and a cost per NIPT of £500 NIPT as contingent
testing appears to offer gains over current DS screening in terms of
fewer procedure-related miscarriages and at no additional cost. A
cost of £500 per NIPT falls within the range that NIPT is
currently offered in the private sector in the UK, and so ought to
be achievable in the NHS. Second, while it produces better
outcomes in terms of DS cases detected and procedure-related
fetal losses, NIPT as first-line screening is more expensive than
current DS screening, even at a very low cost per test. Hence,
NIPT as first-line testing is unlikely to be attractive to NHS
commissioners unless the cost of NIPT was to fall dramatically.
The main uncertainties in our analysis are the uptake of NIPT
under real world conditions and the cost of NIPT. We have also
assumed that the uptake of invasive diagnostic testing after NIPT
is the same as after DS screening. The costs and outcomes of
NIPT for DS as contingent testing and first-line testing compared
with the current DS screening programme ought to be reassessed
once the actual uptake rate of NIPT and the cost of NIPT when
delivered at scale in the NHS are known.
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combined test. 80% uptake of NIPT as contingent screening for
unaffected pregnancies and 90% for affected pregnancies. 69%
uptake of NIPT as first line screening.
(DOC)
Table S2 Outcomes of testing strategies in a screening
population of 10,000 pregnant women with alternative
assumptions for NIPT uptake. 69% uptake of DS screening
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using the combined test. 100% uptake of NIPT as contingent
screening, plus DS screening uptake increases to 79%. 79% uptake
of NIPT as first line screening.
(DOC)
Table S6 CHEERS statement.
(DOC)
Acknowledgments
The original DPT model is available from the NHS Fetal Anomaly
Screening Programme website: http://fetalanomaly.screening.nhs.uk/. We
would like to thank Jan Preece for her editorial assistance.
Author Contributions
Conceived and designed the experiments: SM LSC. Performed the
experiments: NC SK SM. Analyzed the data: NC SK SM. Contributed
reagents/materials/analysis tools: NC MH LSC. Wrote the paper: SM SK
NC MH LSC.
Cost of NIPT for DS
PLOS ONE | www.plosone.org 9 April 2014 | Volume 9 | Issue 4 | e93559
References
1. NHS FASP. Screening for Down’s syndrome: UK NSC policy recommenda-
ations (2011) 2011–2014 Model of Best Practice. Exeter, United Kingdom: NHS
Fetal Anomaly Screening Programme, UK National Screening Committee.
2. Tabor A, Alfirevic Z (2010) Update on procedure-related risks for prenatal
diagnosis techniques. Fetal Diagn Ther 27: 1–7.
3. Lo YMD, Corbetta N, Chamberlain PF, Rai V, Sargent IL, et al. (1997)
Presence of fetal DNA in maternal plsma and serum. Lancet 350: 485–487.
4. Boon EM, Faas BH (2013) Benefits and limitations of whole genome versus
targeted approaches for non-invasive prenatal testing for fetal aneuploidies.
Prenat Diagn 33: 563–568.
5. Ehrich M, Deciu C, Zweifellhofer T, Tynan JA, Cagasan L, et al. (2011) Non-
invasive detection of fetal trisomy 21 by sequencing of DNA in maternal blood: a
study in a clinical setting. Am J Obstet Gynecol 204; 205.e1–11.
6. Palomaki GE, Kloza EM, Lambert-Messerlian GM, Haddow JE, Neveux LM,
et al. (2011) DNA sequencing of maternal plasma to detect Down syndrome: an
international clinical validation study. Genet Med 13: 913–920.
7. Bianchi DW, Platt LD, Goldberg JD, Abuhamad AZ, Sehnert AJ on behalf of
the MatErnal Blood IS Source to Accurately diagnose fetal aneuploidy
(MELISSA) Study Group (2012) Genome-Wide Fetal Aneuploidy Detection
by Maternal Plasma DNA Sequencing. Obstet Gynecol 119: 890–901.
8. Ashoor G, Syngelaki A, Wagner M, Birdir C, Nicolaides KH (2012)
Chromosome-selective sequencing of maternal plasma cell-free DNA for first-
trimester detection of trisomy 21 and trisomy 18. Am J Obstet Gynecol 206:
322.e1–5.
9. Sparks AB, Struble CA, Wang ET, Song K, Oliphant A (2012) Non-invasive
prenatal detection and selective analysis of cell-free DNA obtained from
maternal blood: evaluation for trisomy 21 and trisomy 18. Am J Obstet Gynecol
206: 319.e1–9.
10. Norton ME, Brar H, Weiss J, Karimi A, Laurent LC, et al. (2012) Non-Invasive
Chromosomal Evaluation (NICE) Study: results of a multicentre prospective
cohort study for detection of fetal trisomy 21 and trisomy 18. Am J Obstet
Gynecol 207: 137.e1–8.
11. Futch T, Spinosa J, Bhatt S, de Feo E, Rava RP, et al. (2013) Initial clinical
laboratory experience in non-invasive prenatal testing for fetal aneuploidy from
maternal plasma DNA samples. Prenat Diagn 33: 569–574.
12. Liang D, Lv W, Wang H, Xu L, et al. (2013) Non-invasive prenatal testing of
fetal whole chromosome aneuploidy by massively parallel sequencing. Prenat
Diagn 33: 409–415.
13. ACOG Statement - The American College of Obstetricians and Gynecologists
Committee on Genetics; The Society for Maternal-Fetal Medicine Publications
Committee (2012) Committee Opinion. Obstet Gynecol 120: 1532–1534.
14. Benn PA, Borrell A, Cuckle H, Dugoff L, Gross S, et al. (2012) Prenatal
detection of Down syndrome using massively parallel sequencing (MPS): a rapid
response statement from a committee on behalf of the Board of the International
Society for Prenatal Diagnosis, 24 October 2011. Prenat Diagn 32: 1–2.
15. Langlois S, Brock JA, Genetics Committee, Wilson RD, Audibert F, et al. (2013)
Current status in non-invasive prenatal detection of down syndrome, trisomy 18,
and trisomy 13 using cell-free DNA in maternal plasma. J Obstet Gynaecol Can
35: 177–181.
16. Antenatal Results and Choices (2013) Non-invasive prenatal testing for Down’s
syndrome (NIPT). Available: http://www.arc-uk.org/tests-explained/down-s-
syndrome-screening/non-invasive-prenatal-testing-for-down-s-syndrome. Ac-
cessed 2013 Sep 30.
17. Wald NJ, Bestwick JP (2013) Incorporating DNA sequencing into current
prenatal screening practice for Down’s Syndrome. PLoS ONE 8: e58732.
18. Garfield SS, Armstrong SO (2012) Clinical and cost consequences of
incorporating a novel non-invasive prenatal test into the diagnostic pathway
for fetal trisomies. J Managed Care Med 15; 34–41.
19. Song K, Musci J, Caughey AB (2013) Clinical utility and cost of non-invasive
prenatal testing with cfDNA analysis in hi-risk women based on a US
population. J Matern Fetal Neonatal Med 26: 1180–1185.
20. Ohno M, Caughey AB (2013) The role of non-invasive prenatal testing as a
diagnostic versus a screening tool – a cost-effectiveness analysis. Prenat Diagn
33: 630–635.
21. Cuckle H, Benn P, Pergament E (2013) Maternal cfDNA screening for Down
syndrome – a cost sensitivity analysis. Prenat Diagn 33: 636–642.
22. NHS Fetal Anomaly Screening Programme (2012) Decision planning tool.
A v a i l a b l e : h t t p : / / f e t a l a n o m a l y . s c r e e n i n g . n h s . u k /
costforscreeningstategies#fileid11456. Accessed 2013 Sep 30.
23. NHS Choices (2013). Tests for Down’s syndrome. Available: http://www.nhs.
uk/conditions/pregnancy-and-baby/pages/screening-amniocentesis-downs-
syndrome.aspx#close. Accessed 2014 Feb 6.
24. ONS (2010) Live births in England and Wales by characteristics of mother 2010.
Available: http://www.ons.gov.uk/ons/publications/re-reference-tables.
html?edition = tcm%3A77-230704. Accessed 2013 Sep 30.
25. Morris JK, Mutton DE, Alberman E (2002) Revised estimates of the maternal
age specific live birth prevalence of Down’s Syndrome. J Med Screening 9: 2–6.
26. Rowe R, Puddicombe D, Hockley C, Redshaw M (2008) Offer and uptake of
prenatal screening for Down syndrome in women from different social and
ethnic backgrounds. Prenat Diagn 28: 1245–1250.
27. Chitty LS, Hill M, White H, Wright D, Morris S (2012) Non-invasive prenatal
testing for aneuploidy – ready for prime time? Am J Obstet Gynecol 206: 269–
275.
28. Wright D (2009) DQASS: detection rates and false positive rates for first and
second trimester Down’s syndrome screening tests. Plymouth: Down’s Syndrome
Screening Quality Assurance Support Service (DQASS).
29. Bray I, Wright D (1998) Estimating the spontaneous loss of Down’s syndrome
fetuses between the times of chorionic villus sampling, amniocentesis and live
birth. Prenat Diagn 18: 1045–1054.
30. Gilbert RE, Augood C, Gupta R, Ades AE, Logan S, et al. (2000) Cost-
effectiveness and safety effectiveness of first and second trimester screening
strategies for Down syndrome. London: Systematic Reviews Training Unit,
Centre for Epidemiology and Biostatistics, University of London.
31. Wald NJ, Rodeck CH, Hackshaw AK, Walters J, Chitty LS, et al. (2003) First
and second trimester antenatal screening for Down’s syndrome: the results of the
Serum, Urine and Ultrasound Screening Study (SURUSS). J Med Screen 10:
56–104.
32. Wald NJ, Kennard A, Hackshaw A, McGuire A (1998) Antenatal screening for
Down’s syndrome. London: NHS R&D Health Technology Assessment (HTA)
Programme. Health Technol Assess 2: 1–124.
33. Gray JAM, Ward P (2004) National Downs Syndrome Screening Programme
for England: A Handbook for Staff (Version 2.0). London: UK National
Screening Committee Programme Directorate.
34. Morris JK (2011) The National Down Syndrome Cytogenetic Register for
England and Wales: 2010 Annual Report. London, United Kingdom: Queen
Mary University of London, Barts and The London School of Medicine and
Dentistry.
35. HESonline. Maternity data 2010–11. Available: http://www.hesonline.nhs.uk/
Ease/servlet/ContentServer?siteID=1937&categoryID=1815. Accessed 2013
Sep 30.
36. Department of Health (2011) NHS Reference costs 2008–2009: Appendix
NSRC01 - NHS Trust Reference Cost Schedules. London, United Kingdom:
Crown; 2011 Jan 13. Report No: 15423, 16211.
37. Lewis C, Hill M, Silcock S, Chitty L (2013) Non-invasive prenatal testing for
Down’s Syndrome – pregnant women’s views and likely uptake. Public Health
Genomics 16: 223–232.
38. Chetty S, Garabedian MJ, Norton ME (2013) Uptake of non-invasive prenatal
testing (NIPT) in women following positive aneuploidy screening. Prenat Diagn
33: 542–546.
39. Chitty LS, Kagan KO, Molina FS, Waters JJ, Nicolaides KH (2006) Fetal
nuchal translucency scan and early prenatal diagnosis of chromosomal
abnormalities by rapid aneuploidy screening: observational study. BMJ 332:
452–455.
40. Kagan KO, Chitty LS, Cicero S, Eleftheriades M, Nicolaides KH (2007)
Ultrasound findings before amniocentesis in selecting the method of analysing
the sample. Prenat Diagn 27: 34–39.
Cost of NIPT for DS
PLOS ONE | www.plosone.org 10 April 2014 | Volume 9 | Issue 4 | e93559
